Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

inhibitor of multiple protein tyrosine phosphatases (PTPases), specifically the src homology PTPase (SHP-1 & SHP-2) and PTP1B. Lenocta has also been demonstrated to augment cytokine signaling and responses in hemopoietic cell lines, which can enhance the body's immune system. Preclinical testing of Lenocta has demonstrated anti-tumor activity against a wide spectrum of cancers.

About PTPases

The protein tyrosine phosphatase superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signaling pathways that underlie a broad spectrum of fundamental physiological processes and represent a new class of therapeutic targets. The PTPases SHP-1 and SHP-2 modulate progenitor cell development, cellular growth, tissue inflammation, cellular chemotaxis, and directly control cell survival involving oxidative stress pathways. SHP-1 and SHP-2 are fundamental for the function of several growth factor and metabolic pathways with far reaching implications for disease pathways and disorders such as diabetes, neurodegeneration, and cancer.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits Akt, a member of the serine/threonine-specific protein kinase family that is amplified, overexpressed, and/or activated in prostate, breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1, SHP-2, and PTP1B that has demonstrated clinical and biological activity in solid tumors; and Xyfid(TM), a topical therapy which is being developed for the treatment and prevention of chemotherapy-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing Phase II trials for VQD-002, and
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... AMBLER, Pa. , July 10, 2014 /PRNewswire/ ... visited Moberg Research,s (Moberg) medical device manufacturing facility. ... how Moberg,s advanced neurological monitors facilitate cutting-edge research ... 2011, Rep. Kennedy and mental health advocate, ... non-profit organization dedicated to fostering fundamental changes that ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ... ... ... ...
... ... ... ... , , ...
Cached Medicine Technology:Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 2Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 3Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 4Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 5Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 6Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 7Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 8Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 9Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 10Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 11Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 12Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 13Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop 2Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop 3
(Date:7/10/2014)... (PRWEB) July 11, 2014 The Capital ... has performed the first procedure in a clinical trial ... inserted in the leg. , During the procedure, done ... Veznedaroglu, an endovascular neurosurgeon, threaded a tiny catheter through ... the body and neck and into the brain. Once ...
(Date:7/10/2014)... acids had healthier joints than those fed diets high ... to Duke Medicine researchers. , The findings, published in ... on July 11, 2014, suggest that unhealthy dietary fats ... osteoarthritis. , "Our results suggest that dietary factors play ... link between obesity and osteoarthritis," said Farshid Guilak, Ph.D., ...
(Date:7/10/2014)... More than 200 experts on aggression, ... street violence, will attend the 21st World Meeting of ... (ISRA) at the Loews Atlanta Hotel, July 15-19. , ... world meeting, which is held every other year on ... together leading scholars from more than 20 different countries, ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Fatigue, ... for an increasing number of accidents in the ... Safety Reboot. The articles highlight safety issues that ... 317 million accidents occur on the job annually, ... features continue to explore "preventable workplace accidents." , ...
(Date:7/10/2014)... Wisconsin (PRWEB) July 10, 2014 Ticketability.com has ... Tour,” and now Paul McCartney tickets for San Diego are ... in San Diego since 1976, and the newly added September ... California fans. , Click Here to view the ... tickets for Petco Park will become available to the general ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2
... Every Birth is Safe for Pregnant Women , ... , , ... ... NEW YORK , March 22 ...
... ... ... ... WASHINGTON , March 22 With the passage of the historic health care legislation, the National Medical ...
... has been a major increase in the incidence of ... differing opinions as to why this is (environment, vaccines, ... are still many children who have autistic traits that ... the support they need through educational or health services. ...
... Cycling jerseys and ... ... announced today the addition of a durable, visible and practical backpack for cyclists with ... to help remind motorists to give cyclists at least 3 feet clearance when passing them from ...
... and Services for the Aging, on passage of Health Reform Legislation: , ... , , ... ... "We commend the U.S. ...
... Capital 2010 High Yield Bond and Syndicated Loan Conference in Phoenix, Ariz. , on March 24-26, 2010 . , ... , , ... ... HealthSouth Senior Vice ...
Cached Medicine News:Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 2Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 3Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 4Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 5Health News:National Medical Association, Health System Reform - From Legislation to Implementation 2Health News:National Medical Association, Health System Reform - From Legislation to Implementation 3Health News:New Backpack for Cyclists Sends a Polite Message to Motorists: '3 Feet Please' 2Health News:New Backpack for Cyclists Sends a Polite Message to Motorists: '3 Feet Please' 3Health News:AAHSA Statement on Passage of Health Reform Legislation 2Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 2Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 3
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... Sgarlato Lab's bring a new standard in the ... by Sgarlato Labs. Made of medical grade silicone, ... patient with a high level of flexibility while ... Rods are available in varying stiffnesses. Lengths are ...
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... has been approved for use as an ... seizures in adults and adolescents over 12 ... that are refractory to antiepileptic medications. This ... controlled, clinical trials. Efficacy, measured as median ...
Medicine Products: